Banyu Pharmaceutical Co. Ltd

Other

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Microbial Chemistry Research Foundation

Hiroyoshi Hidaka

Ikuo Matsumoto

Junji Yoshizawa

Hamao Umezawa

Tomio Takeuchi

Hajime Morishima

Toshiharu Nagatsu

Shuichi Iwadare

Masa Hamada

Takaaki Aoyagi

Masaaki Ishizuka

Masaaki Hosoi

Shigenori Kotani

Nobuo Aoki

Takuzo Yamamoto

Yoshiaki Ito

Kiyofumi Ishikawa

Mitsuo Yano

Yoshimi Tsuchiya

Kyoko Nakamichi

Nobuo Harada

Yukio Hirayama

Kaoru Shimada

Nobuyuki Mino

Hirotaro Narabayashi

Koji Tomimoto

A solid electrolytic capacitor includes a package for entirely sealing a capacitor element , an anode lead terminal connected to an anode wire of the capacitor element , and a cathode lead terminal kept in close contact with a side surface of the capacitor element, wherein both leads are exposed at the bottom surface of the package. The anode lead terminal is formed with an upwardly bent piece provided with a positioning groove . The anode wire of the capacitor element is fitted in the positioning groove, so that the upwardly bent piece completely bridges the gap between the anode wire and the anode lead terminal while accurately positioning the capacitor element at the center widthwise of the anode lead terminal and the cathode lead terminal.

Structure of surface-mounting solid electrolytic capacitor and method of making the same

DL- or L-Threo-3-(3,4-dihydroxyphenyl)-N-methyl-serine which may also be termed as DL- or L-threo-adrenalinecarboxylic acid are now provided, which are new compounds useful for therapeutic treatment of Parkinson's disease and mental depression disease. DL-Adrenalinecarboxylic acid may be produced by a new process comprising reacting glycine with O-protected 3,4-dihydroxybenzaldehyde, hydrolyzing the resultant reaction product under acidic conditions to form O-protected DL-3-(3,4-dihydroxyphenyl)serine, isolating the O-protected DL-3-(3,4-dihydroxyphenyl)serine into the threo isomer and the erythro isomer by recrystallization from a suitable organic solvent, introducing an unsubstituted or substituted benzyl group into the 2-amino group of the resulting O-protected DL-threo-3-(3,4-dihydroxyphenyl)serine, then N-methylating the resulting O-protected DL-threo-3-(3,4-dihydroxyphenyl )-N-benzylserine, and removing the O-protecting groups as well as the unsubstituted or substituted benzyl group at the 2-methylamino group of the N-methylation product. L-Adrenalinecarboxylic acid may be produced by a new process comprising introducing a p-methoxybenzyloxycarbonyl group into the 2-amino group of the O-protected DL-threo-3-(3,4-dihydroxyphenyl)serine obtained as an intermediate product, optically resolving the resultant O-protected DL-threo-3-(3,4-dihydroxyphenyl)-N-p-methoxybenzyloxycarbonyl-serine by reacting the latter with an optically active amine and recrystallizing the resultant amine salt products from a suitable organic solvent, removing the p-methoxy-benzyloxycarbonyl group from the resultant O-protected L-threo-(3,4-dihydroxyphenyl)-N-p-methoxybenzyloxycarbonyl-serine, reacting the resultant O-protected L-threo-(3,4-dihydroxyphenyl)serine with dimethyl sulfate in dry acetone to form an O-protected L- or D-threo-(3,4-dihydroxyphenyl)-N-methylserine methyl ester, saponifying this methyl ester and then removing the O-protecting groups from the saponification product.

Threo-adrenalinecarboxylic acid, and the production and uses thereof

L-aminoacylases S.sub.1 and S.sub.2 derived from actinomycetes and having physicochemical characteristics such that it is a L-aminoacylase which acts on a N-acyl-L-amino acid to give a L-amino acid, its substrate profile is wide, and it acts not only on a N-acyl derivative of a natural L-amino acid, but also on a N-acyl derivative of a synthetic L-amino acid, while it does not act on a N-acyl-D-amino acid, a DL-N-acetyl-.alpha.methylbenzylamine and a N-acetyl-D-glucosamine, etc.

L-aminoacylases

N-acyl-DL-3-(3,4-dihydroxyphenyl)serine or a catecholic hydroxyl-protected derivative thereof is stereospecifically de-acylated by reaction with a microorganism of the genus Streptomyces or Streptoverticillium having an acylase or with an extract of said microorganism containing said acylase, to produce L-3-(3,4-dihydroxyphenyl)serine or the hydroxyl-protected derivative thereof, with the N-acyl-D-3-(3,4-dihydroxyphenyl)serine compound remaining unaltered. The L-3-(3,4-dihydroxyphenyl)serine compound so produced can be separated from the N-acyl-D-3-(3,4-dihydroxyphenyl)serine compound owing to the difference in the properties of them.

Process for microbial production of an optically active

A 1,3-dithiol-2-ylidene derivative of the formula: ##STR1## wherein each of R and R.sup.1 which may be the same or different, is a lower alkyl group, a lower alkenyl group, a cycloalkyl group, a lower alkoxyalkyl group, or a substituted or unsubstituted aryl, aralkyl or heterocyclic group, or R and R.sup.1 together form a substituted or unsubstituted ethylene or trimethylene group.

Anti-hepatitis and anti-cirrhotic 1,3-dithiol-2-ylidene derivatives, and

An .alpha.-tocopheryl 5-substituted picolinate of the formula ##STR1## wherein R represents an alkyl group which may have a substituent, a lower alkenyl group, a phenyl(lower alkyl) group, or a phenyl group which may have a substituent, and Q represents a methylene group or an oxygen or sulfur atom, or a pharmaceutically acceptable acid addition salt thereof. This compound can be produced by reacting a substituted picolinic acid of the formula ##STR2## wherein R and Q are as defined above, or its reactive derivative with .alpha.-tocopherol of the formula ##STR3## and as required, contacting the resulting compound with a pharmaceuticlly acceptable acid. A pharmaceutical composition comprising said compound as an active ingredient is useful for the treatment of hypertension.

.alpha.-Tocopheryl ester of 5-substituted picolinic acid and hypotensive

An N-acyl-3-[4-(benzoylalkyl)piperazin-1-yl]-sydnonimine compound represented by the following formula ##STR1## wherein R.sup.1 represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms,

N-Acyl-3-[4-(benzoylalkyl)piperazin-1-yl]-sydnonimine compound, process

A 3-[4-(benzoylalkyl)piperazin-1-yl]sydnonimine compound represented by the following formula ##STR1## wherein R represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, and n represents zero or an integer of 1 to 10, and its acid addition salt. The above sydnonimine compounds are useful for the treatment of troubles of the circulatory system and can be produced by contacting a 4-(benzoylalkyl)-1-(N-nitrosocyanomethylamino)piperazine represented by the following formula ##STR2## wherein R and n are as defined, with an acid.

Syndonimine derivatives, process for production thereof, and use thereof

A new compound is produced which has the general formula: ##STR1## wherein R represents hydrogen atom or a lower alkyl group and which exhibits an immunopotentiating activity. This new compound as well as its pharmaceutically acceptable salts and hydrates are useful for immunotherapy and treatment of immune diseases and disorders in living animals including human beings. The new compound can be produced by reduction of a hydroxyterephthalic acid alkyl ester or by esterification of the corresponding 3-hydroxy-4-(hydroxymethyl)-benzoic acid.

Compound with immunopotentiating activity and production and uses thereof

A new compound having the formula ##STR1## and now designated forphenicinol is produced, which exhibits an immunopotentiating activity. This new compound as well as its pharmaceutically acceptable salts and hydrates are useful for immunotherapy and treatment of immune diseases and disorders in living animals, including human beings. The new compound can be produced by hydrolysis of the corresponding aminonitrile compound of the formula ##STR2## or by reduction of forphenicine.

Growing community of inventors

Tokyo, Japan

Ikuo Matsumoto